Trial reportCancer causes & control : CCC2011
Serum total and HDL cholesterol and risk of prostate cancer.
Trial report in Cancer causes & control : CCC, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Plasma total cholesterol concentration and risk of higher-grade prostate cancer: A nested case-control study and a dose-response meta-analysis.International journal of cancer · 2023Pooled it
- Prognostic value of lipid profiles after radical prostatectomy: a systematic review and meta-analysis.Lipids in health and disease · 2019Pooled it
- Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis.Journal of endocrinological investigation · 2013Pooled it
- Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study.Prostate cancer and prostatic diseases · 2018Trial
- 27-Hydroxycholesterol in cancer development and drug resistance.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Association between high‑density lipoproteins and prostate specific antigen: A cross‑sectional study from NHANES database.Molecular and clinical oncology · 2025Article
- Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study.Scientific reports · 2025Article
- Impact of thyroid hormone replacement on the risk of second cancer after thyroidectomy: a Korean National Cohort Study.Scientific reports · 2023Article
- Associations between serum high-density lipoprotein cholesterol levels and cause-specific mortality in a general population of 345 000 men and women aged 20-79 years.International journal of epidemiology · 2023Article
- Impact of thyroid cancer on the cancer risk in patients with non-alcoholic fatty liver disease or dyslipidemia.Scientific reports · 2023Article
- Article
- Article
- Associations of preoperative serum high-density lipoprotein cholesterol and low-density lipoprotein cholesterol levels with the prognosis of ovarian cancer.Archives of gynecology and obstetrics · 2022Article
- Construction and validation of a clinical predictive nomogram for intraductal carcinoma of the prostate based on Chinese multicenter clinical data.Frontiers in oncology · 2022Article
- Prognostic value of nutritional and inflammatory indicators in females with esophageal squamous cell cancer: A propensity score matching study.Frontiers in genetics · 2022Article
- Impact of Dyslipidemia on the Risk of Second Cancer in Thyroid Cancer Patients: A Korean National Cohort Study.Annals of surgical oncology · 2021Article
- Apolipoprotein mimetics in cancer.Seminars in cancer biology · 2021Review
- Using Elevated Cholesterol Synthesis as a Prognostic Marker in Wilms' Tumor: A Bioinformatic Analysis.BioMed research international · 2021Article
- Fibronectin-containing High-Density Lipoprotein is Associated with Cancer Cell Adhesion and Proliferation.The Kobe journal of medical sciences · 2020Article
- Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).Gynecologic oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundStudies suggest a decreased risk of high-grade prostate cancer in men with lower circulating total cholesterol and that statins may protect against aggressive disease. Confirmation in additional populations and examination of associations for lipoprotein subfractions are needed.
methodsWe examined prostate cancer risk and serum total and HDL cholesterol in the ATBC Study cohort (n = 29,093). Cox proportional hazards models were used to estimate the relative risk of total (n = 2,041), non-aggressive (n = 829), aggressive (n = 461), advanced (n = 412), and high-grade (n = 231) prostate cancer by categories of total and HDL cholesterol.
resultsAfter excluding the first 10 years of follow-up, men with higher serum total cholesterol were at increased risk of overall (≥240 vs. <200 mg/dl: HR = 1.22, 95% CI 1.03-1.44, p-trend = 0.01) and advanced (≥240 vs. <200 mg/dl: HR = 1.85, 95% CI 1.13-3.03, p-trend = 0.05) prostate cancer. Higher HDL cholesterol was suggestively associated with a decreased risk of prostate cancer regardless of stage or grade.
conclusionsIn this population of smokers, high serum total cholesterol was associated with higher risk of advanced prostate cancer, and high HDL cholesterol suggestively reduced the risk of prostate cancer overall. These results support previous studies and, indirectly, support the hypothesis that statins may reduce the risk of advanced prostate cancer by lowering cholesterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.